Revision of PRECAUTIONS
Minocycline hydrochloride (oral dosage form, injections)

July 20, 2023

Therapeutic category
Antibiotic preparations acting mainly on gram-positive, gram-negative bacteria, and rickettsia and chlamydia

Non-proprietary name
Minocycline hydrochloride

Safety measure
PRECAUTIONS should be revised.
### Adverse Reactions

#### Clinically Significant Adverse Reactions

<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exacerbation of systemic lupus erythematosus (SLE)-like symptoms:</strong></td>
<td><strong>Lupus-like syndrome:</strong></td>
</tr>
<tr>
<td>Exacerbation of systemic lupus erythematosus (SLE)-like symptoms may occur. If these symptoms occur, administration of this drug should be discontinued, and appropriate measures should be taken.</td>
<td>Lupus-like syndrome may occur. If these symptoms occur, administration of this drug should be discontinued, and appropriate measures should be taken. Cases have been reported more frequently, especially in long-term treatment cases where this drug has been used for more than 6 months.</td>
</tr>
</tbody>
</table>

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.